Similar articles

• Treatment of refractory stage IV mycosis fungoides with bexarotene monotherapy.

  Otremba B. Otremba B. Dermatol Clin. 2008 Jan;26 Suppl 1:51-2. Dermatol Clin. 2008. PMID: 18405188 No abstract available.
• Bexarotene monotherapy for patients with advanced stage mycosis fungoides.

  Bachelez H. Bachelez H. Dermatol Clin. 2008 Jan;26 Suppl 1:25-6. Dermatol Clin. 2008. PMID: 18405183 No abstract available.
• Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon/PUVA and methotrexate.

  Dalle S, Thomas L. Dalle S, et al. Dermatol Clin. 2008 Jan;26 Suppl 1:39-41. Dermatol Clin. 2008. PMID: 18405186 No abstract available.
• Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.

  Coors EA, Von den Driesch P. Coors EA, et al. Br J Dermatol. 2005 Jun;152(6):1379-81. doi: 10.1111/j.1365-2133.2005.06616.x. Br J Dermatol. 2005. PMID: 15949024 Review. No abstract available.
• CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.

  Gopaluni S, Perzova R, Abbott L, Farah R, Shrimpton A, Hutchison R, Poiesz BJ. Gopaluni S, et al. Am J Hematol. 2008 Sep;83(9):744-6. doi: 10.1002/ajh.21231. Am J Hematol. 2008. PMID: 18615708 Review.